Brief: Timber Pharmaceuticals Announces Positive End-Of-Phase 2 Meeting With FDA For Tmb-001 In Moderate To Severe Congenital Ichthyosis
03/02/2022 13:31
Feb 3 (Reuters) - Timber Pharmaceuticals Inc TMBR.A :
* TIMBER PHARMACEUTICALS ANNOUNCES POSITIVE END-OF-PHASE 2
MEETING
WITH FDA FOR TMB-001 IN MODERATE TO SEVERE CONGENITAL ICHTHYOSIS
Source text for Eikon: ID:nGNX3tCSLr
Further company coverage: TMBR.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Trex Wind-Down
See all newsBrief: NYSE American To Suspend Trading Immediately In Timber Pharma
Brief: Timber Pharmaceuticals Receives Court Approval Of All “First Day” Motions To Support Business
Brief: NYSE American to Commence Delisting Proceedings Against Timber Pharmaceuticals
Brief: Timber Pharmaceuticals Says Prior To Filing Of Chapter 11 Case, Debtors Entered Into A "Stalking Horse" Asset Purchase Agreement
Brief: Timber Pharmaceuticals Inc Files For Voluntary Chapter 11 Bankruptcy - Court Filing